Biogen (WBO:BIIB) Beneish M-Score: -2.68 (As of Jun. 26, 2026)


WBO:BIIB Biogen Inc WBO:BIIB
72 GF Score
Price €180.54
GF Value €171.49
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Beneish M-Score?

Biogen WBO:BIIB +2.45% 72 Beneish M-Score is -2.68 as of Jun. 26, 2026. GuruFocus rates WBO:BIIB with a GF Score™ of 72/100 and a GF Value™ of €171.49 (Fairly Valued). The stock has 7 warning signs investors should review. Among 911 Drug Manufacturers companies, Biogen ranks better than 66.52% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.68 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Biogen's Beneish M-Score or its related term are showing as below:

WBO:BIIB' s Beneish M-Score Range Over the Past 10 Years
Min: -2.93   Med: -2.62   Max: -2.18
Current: -2.68

During the past 13 years, the highest Beneish M-Score of Biogen was -2.18. The lowest was -2.93. And the median was -2.62.


Biogen Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Biogen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Beneish M-Score Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.91 -2.22 -2.30 -2.77 -2.50

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.49 -2.63 -2.50 -2.68

WBO:BIIB vs OGN, AMRN, SCLX: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Biogen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biogen's Beneish M-Score falls into.


WBO:BIIB
72GF Score
Biogen Inc WBO:BIIB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biogen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8937+0.528 * 1.0014+0.404 * 0.9562+0.892 * 0.9383+0.115 * 0.8665
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0166+4.679 * -0.022363-0.327 * 0.8939
=-2.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €1,549 Mil.
Revenue was 2143.297 + 1946.608 + 2159.564 + 2293.648 = €8,543 Mil.
Gross Profit was 1571.532 + 1523.451 + 1584.976 + 1769.113 = €6,449 Mil.
Total Current Assets was €7,950 Mil.
Total Assets was €25,503 Mil.
Property, Plant and Equipment(Net PPE) was €2,828 Mil.
Depreciation, Depletion and Amortization(DDA) was €689 Mil.
Selling, General, & Admin. Expense(SGA) was €2,121 Mil.
Total Current Liabilities was €2,594 Mil.
Long-Term Debt & Capital Lease Obligation was €5,676 Mil.
Net Income was 276.367 + -41.761 + 397.458 + 550.372 = €1,182 Mil.
Non Operating Income was -45.326 + -351.165 + -11.417 + -58.522 = €-466 Mil.
Cash Flow from Operations was 558.357 + 437.163 + 1084.17 + 139.5 = €2,219 Mil.
Total Receivables was €1,847 Mil.
Revenue was 2248.675 + 2344.239 + 2221.686 + 2289.892 = €9,104 Mil.
Gross Profit was 1666.572 + 1786.996 + 1646.217 + 1782.658 = €6,882 Mil.
Total Current Assets was €7,054 Mil.
Total Assets was €25,931 Mil.
Property, Plant and Equipment(Net PPE) was €3,218 Mil.
Depreciation, Depletion and Amortization(DDA) was €658 Mil.
Selling, General, & Admin. Expense(SGA) was €2,224 Mil.
Total Current Liabilities was €4,900 Mil.
Long-Term Debt & Capital Lease Obligation was €4,507 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1548.696 / 8543.117) / (1846.762 / 9104.492)
=0.18128 / 0.202841
=0.8937

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6882.443 / 9104.492) / (6449.072 / 8543.117)
=0.755939 / 0.754885
=1.0014

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7949.696 + 2827.858) / 25502.881) / (1 - (7054.05 + 3217.89) / 25930.617)
=0.577399 / 0.603868
=0.9562

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=8543.117 / 9104.492
=0.9383

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(657.501 / (657.501 + 3217.89)) / (688.509 / (688.509 + 2827.858))
=0.169661 / 0.195801
=0.8665

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2121.094 / 8543.117) / (2223.59 / 9104.492)
=0.248281 / 0.24423
=1.0166

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5676.043 + 2594.048) / 25502.881) / ((4506.692 + 4900.095) / 25930.617)
=0.324281 / 0.362768
=0.8939

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1182.436 - -466.43 - 2219.19) / 25502.881
=-0.022363

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biogen has a M-score of -2.74 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.68 mean?
Biogen (WBO:BIIB) has a Beneish M-Score of -2.68 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Biogen and its competitors. According to the industry distribution chart, Biogen ranks #305 out of 911 companies in the Drug Manufacturers industry, placing it in the top 33.5%.
Is Biogen's Beneish M-Score too high?
Biogen's current Beneish M-Score is -2.68. Based on the distribution chart, Biogen ranks #305 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogen has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Beneish M-Score compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #305 out of 911 companies for Beneish M-Score. This puts Biogen in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Biogen and its competitors. Biogen's current Beneish M-Score is -2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (WBO:BIIB) is currently considered Fairly Valued. The stock's GF Value™ is €171.49, compared to a current price of €180.54 — trading 5.3% above its estimated fair value. The current Beneish M-Score is -2.68. Biogen's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Biogen (WBO:BIIB), the current Beneish M-Score is -2.68 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (WBO:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €180.54 is trading 5.3% above its estimated GF Value™ of €171.49. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for WBO:BIIB:

  • Beneish M-Score: -2.68
  • GF Value™: €171.49 vs. price of €180.54 (5.3% above fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the WBO:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
72GF Score

Get the complete analysis for WBO:BIIB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€180.54
Price
€171.49
GF Value